Candel Therapeutics Inc. stock ended Wednesday deep in the red but rose 1.3% in extended trading after the company announced ...

The first-line combination of amivantamab-vmjw plus lazertinib extended OS compared with osimertinib for patients with EGFR-mutated advanced non-small cell lung cancer, according to data from the ...

Systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved a 71% disease control rate (5/7) with two partial ...

Positive preliminary data from the phase 1b/2 trial evaluating Olvi-Vec in small cell lung cancer have been announced.

Lung Cancer Test Predicts Survival in Early Stages ... 2024 — A laboratory study provides evidence about how advanced age can be protective against cancer -- with implications for treating ...

The first patient has been dosed in the phase 3 TACTI-004 trial evaluating efti with Keytruda and chemotherapy for advanced ...

Research assessing the nutritional status and impact of interventions for patients with lung cancer found that most exhibit ...

The New York State Senate has unanimously passed Senate Bill S. 2000, a significant step toward improving the early detection ...

First patient safely dosed at Calvary Mater Newcastle Hospital in Australia, marking a significant milestone for ImmutepGlobal Phase III with ...

Neuroendocrine tumors that start in the pancreas tend to be more aggressive and have a poor prognosis.

Results from multiple clinical trials showed that Tagrisso demonstrated survival benefits in EGFR-mutated non-small cell lung ...

Genelux and Newsoara Announce Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer Genelux Corporation Tue, Mar 25, 2025, 5:30 AM 8 min read ...